JUL 31, 2018 05:45 PM PDT

Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?

Researchers have been examining the loss of control over the DNA replication and cell proliferation process since it was connected to the development of cancer.  One of the most well-known and common traits of the disease in all types of cancer diagnoses is this this uncontrolled cellular replication and growth. 

In healthy cells, this process is carefully regulated and controlled through pathways and cellular checkpoints.  In a Nature Communications article published July 17, 2018, researchers identified a replication initiation determinant protein (RepID) that regulates replication through association of other proteins, drawing them directly to chromatin sites for replication initiation.  One of these proteins is a Culling-RING E3 ubiquitin ligase (CRL) which one of many CRLs.  CRL4 is recruited by RepID to chromatin in the very early stages of mitosis (cell cycle) prior to replication.  CRL4 acts to degrade CDT1, a protein that promotes replication at the appropriate time in the cell cycle.  Loss of CDT1 is the switch that tells a cell to only begin the DNA replication cycle once.  In addition to CRLs, a complex called SCF is also part of the cell cycle progression in mammals.  It, too, can facilitate degradation of chromatin proteins involved in regulation of mitosis and DNA replication later in the cell cycle (the S-phase).

In cases of RepID loss of expression or function, turning off that CDT1 switch is up to the SCF complex later in the cell cycle.  However, because the degradation was originated after DNA replication began, the cell re-replicated its DNA because there were higher levels of CDT1 associated with the chromatin.

Part of the SCF complex is a protein called SKP2.  This group of researchers treated the depleted RepID cancer cell cultures with a drug that inhibits SKP2, known as SZL-P1-41.  Their findings indicated that cells expressing intact RepID were not affected by the SKP2 inhibitor but cells with no RepID showed high sensitivity to SKP2 inhibition. The RepID knockout cells entered apoptosis and there were no surviving colonies in cell culture.  The researchers conclude that, “RepID expression levels might modulate the sensitivity of cancer cells to cullin-targeting drugs.”

Sources: Nature Communications, National Cancer Institute,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 19, 2018
Cancer
JUN 19, 2018
Cancer-Related Cognitive Impairment aka "ChemoBrain" Needs YOU!
There is a need for neuroscientists to investigate what is known as chemobrain; survivors and providers are looking for ideas for approaches to mitigating this late effect chemo related issue...
JUN 26, 2018
Cancer
JUN 26, 2018
Genomic Markers Identified for Infant Soft Tissue Tumors
A new article from Nature Communications published on June 18, 2018 now outlines a newly discovered connection between infant soft tissue tumors and the mutations involving EGFR and BRAF gene...
JUN 27, 2018
Infographics
JUN 27, 2018
The Role of Biomarkers In Modern Medicine
A biomarker (short for biological marker) is a measurable indicator of some biological state or condition. The biomarker can be measured objectively and consistently. Biomarkers play signific...
JUL 03, 2018
Cancer
JUL 03, 2018
Hereditary Myeloid Neoplasm Predisposition
New changes in myeloid classification help to outline a new category of AML which develops as a result of hereditary mutations predisposing family members to myeloid neoplasms in adulthood....
JUL 26, 2018
Genetics & Genomics
JUL 26, 2018
When a Cancer Gene Switches Sides
All cells carry a gene named p53, which has a vital role in shielding the body from cancer. But it can betray cells too....
SEP 26, 2018
Cancer
SEP 26, 2018
Rare Cancer the Focus of Mesothelioma Awareness Day
More than 2,500 Americans are diagnosed with mesothelioma cancer each year. The cancer is rare but very serious - most patients diagnosed with the disease live just a short 12 to 21 months....
Loading Comments...